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ABSTRACT 
Purpose of review: Pain is one of the most common and feared symptoms associated with a 
new diagnosis of cancer and its subsequent treatment. Unfortunately, it remains 
undertreated in around one third of patients. It has been recently postulated that one 
mechanism for this could be failure to recognise neuropathic pain. One attractive option in 
both the case of neuropathic pain and pain associated with intolerable side effects of 
prescribed opioids is the use of ‘topiceuticals’, as a means of targeted pain relief with 
potentially fewer side effects. This review summarises the evidence base for the various 
topiceuticals available for the treatment of localised neuropathic pain. 
Recent findings: The recent evidence base for established treatments such as capsaicin and lignocaine 
is examined. A variety of novel and previously used therapies are considered. 
Summary: The use of topiceuticals in localised neuropathic pain associated with malignancy 
remain a valuable option with many advantages over systemic treatments. In addition to 
anecdotal reports of efficacy, there is a growing body of evidence to consider the early use of 
topical lignocaine and capsaicin in this context. The authors’ have proposed a guideline 
including the use of topiceuticals to aid in the management of neuropathic pain 
 
KEYWORDS 
Topiceuticals, cancer, pain, topical, therapy  
INTRODUCTION 
Pain is one of the most common and feared symptoms associated with a new diagnosis of 
cancer and its subsequent treatment[1]. Unfortunately, some 30 years since the advent of 
the World Health Organisation’s palliative pain ladder, it remains undertreated in around one 
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third of patients [2,3]. Whilst for many an approach using the analgesic ladder will alleviate 
symptoms, there are many for whom strong opioids fail to control pain. It has been recently 
postulated that one mechanism for this could be failure to recognise neuropathic pain and 
targeting treatment towards it [4]. Sources of neuropathic pain in this population include 
chemotherapy induced peripheral neuropathy and chronic post-surgical pain (which includes 
scar hypersensitivity) from curative and palliative surgeries. For a significant number of 
patients, pain may be ameliorated with strong opioid analgesics, but this may be at the 
expense of intolerable side effects. Options available to the Palliative and Pain Physicians in 
such scenarios include invasive interventions such as intra-thecal drug delivery (ITDD), 
cordotomy and coeliac plexus block. Such an approach requires input from a multidisciplinary 
team in a specialist centre[5]. One attractive option in both the case of neuropathic pain and 
pain associated with intolerable side effects of prescribed opioids is the use of ‘topiceuticals’, 
as a means of providing targeted pain relief with potentially fewer side effects. 
BACKGROUND 
The use of topical remedies is not a new concept. In prehistoric times, humans recognised 
that local flora and fauna could be applied to wounds and passed this knowledge down 
through the generations[6]. In the context of this article, topical, from the greek topikos (of a 
place) refers to the local application of a medication to the tissues to achieve high 
concentrations and thus effect at the target site. This is in contrast to transdermal therapy 
which aims to achieve steady systemic absorption of a medication, typically through the 
application of an adhesive patch to the skin. Commonly used topiceuticals include Non-
Steroidal Anti-Inflammatory Drugs (NSAIDS), the Lidocaine 5% plaster (Versatis®), Capsaicin 
cream 0.025% and 0.075% and the Capsaicin 8% patch (Qutenza®). 
WHEN TO USE TOPICEUTICALS? 
The multi-factorial nature of the pain experience associated with malignancy and the plethora 
of sources that pain can present from, are beyond the scope of this text. There are, however, 
several scenarios where adjuvant analgesics may be useful. These include bone pain 
(bisphosphonates, radiopharmaceuticals), bowel obstruction (anticholinergic drugs, 
somatostatin analogues), cerebral oedema (dexamethasone), and neuropathic pain 
(anticonvulsants, antidepressants) [7]. It is also in the case of the latter where topiceuticals 
can be a useful adjunct. 
In a systematic review of over 13,000 cancer patients the prevalence of neuropathic pain was 
estimated to be between 19 and 39% [4]. A rational approach to the treatment of neuropathic 
pain is described in the most recent NICE guidelines[8]. This details a stepwise approach using 
systemic treatments such as anticonvulsants and antidepressants. However, it has recently 
been noted that just over half of cancer patients with neuropathic pain will have a consistent 
and circumscribed area of maximum pain[9]. It is this ‘localised neuropathic pain’ (LNP) that 
forms the basis for using topiceuticals in cancer-related pain. 
WHY USE A TOPICAL TREATMENT? 
The need for further strategies such as topical treatment is borne out of the difficult nature 
of treating neuropathic pain. Even amongst the commonly used and most effective systemic 
analgesics such as the tricyclic antidepressants and gabapentinoids, the number-needed to 
treat (NNT) to achieve a 50% pain reduction varies from three to seven or greater [10]. These 
medications are not without side effects which limit their use. 
Topiceuticals have a theoretical pharmacokinetic and pharmacodynamic advantage because 
they result in low systemic drug absorption, thus potentially less side effects and reduced 
drug-drug interactions. This property also infers a safer profile for use in patients with liver 
and renal dysfunction. There is generally no requirement or delay in therapy to titrate the 
dose for the available formulations and similarly no dose reduction for patients with co-
morbid disease. It is arguably simpler to apply a topical treatment in comparison to 
medications, which often require dose titration and re-adjustment. The dosing schedule can 
also be significantly less frequent than oral medication, e.g. once daily for lidocaine plasters 
or even three monthly for  the capsaicin 8% patch, Qutenza ®. Furthermore this offers a route 
of treatment in those with an inability to swallow or absorb systemic medications. Another 
benefit perhaps less commonly considered in the context of malignancy, but more pertinent 
to persistent non-malignant pain, is that topical treatments are generally not likely to be 
associated with misuse or abuse. 
A simple screening tool has been devised to aid in the initiation of topical treatment for 
localised neuropathic pain[table 1]. A numerical score of ‘4’ based on history, examination 
and size of the affected area suggests a diagnosis of LNP and consideration can be given to 
the various agents available described below.  
NSAIDS 
Non-steroidal anti-inflammatory drugs are among the most prevalent topical agents, being 
readily available in ‘over the counter’ preparations without a prescription in the United 
Kingdom. They exert their action via inhibition of prostaglandin synthesis in a mechanism 
involving the opening of adenosine triphosphate sensitive potassium channels [12,13]. This 
inflammatory property explains their demonstrated efficacy in randomised controlled trials 
for treating conditions characterised by somatic nociceptive pain such as tendonitis [14] and 
acute soft tissue injuries [15]. It is perhaps unsurprising that there is a paucity of evidence for 
their use in neuropathic pain. A small numbered double-blind crossover placebo-controlled 
study demonstrated that aspirin was significantly better than placebo for treating both acute 
and post-herpetic neuralgia, whereas diclofenac was not[16]. In the authors’ experience 
NSAIDS are not generally considered successful in the treatment of localised neuropathic pain 
and there is not a significant body of evidence to support their use in this context. 
LIDOCAINE  
Local anaesthetics exert their action through the preferential blockade of active sodium 
channels present in the neuronal cell membrane[17]. Recently the role of various sodium 
channel subtypes has been characterised and described with a postulated mechanism 
involving neuronal excitability and lowering of the action potential threshold to explain 
spontaneous pain and the peripheral and central sensitisation seen in chronic neuropathic 
pain states [18]. The commonly used topical local anaesthetic preparations include the 5% 
lidocaine Versatis™ plaster, the eutectic mixture of local anaesthetics (EMLA); containing 
2.5% priclocaine/2.5% lidocaine), and the Synera™ tetracaine 70mg/lidocaine 70mg patch. 
The bulk of the evidence for the lidocaine patches comes from short duration trials in the 
context of post-herpetic neuralgia (PHN). A double blind placebo-plaster controlled trial of 
265 patients found the lidocaine plaster to be a safe treatment associated with benefits in 
pain, allodynia, sleep and quality of life [19]. Another retrospective study of the lidocaine 5% 
plaster comprising a cohort of 467 patients with peripheral neuropathic pain from a variety 
of causes, demonstrated that pain intensity was reduced by 50% in 45.5% of patients, and 
reduced by 30% in 82.2% of patients [20]. Side effects observed in the latter included 
erythema (n=19),  pruritis (n=11), burns (n=12) and oedema (n=4) representing a relatively 
good safety profile. In a retrospective audit of 97 patients within a comprehensive cancer 
centre, lidocaine plasters were found to be particularly efficacious in patients with allodynia 
[21]. Although a substantial evidence base for the use of lidocaine plasters in LNP secondary 
to cancer or treatment complications of cancer is lacking, it is the authors’ experience that it 
is a safe and efficacious treatment in those with positive sensory signs. It is a useful second 
line treatment but can be considered first line in the elderly and frail. 
CAPSAICIN 
Capsaicin, an active ingredient of chilli peppers from the genus capsaicum , is a colourless 
odourless, volatile, hydrophobic compound. It was first isolated in 1816 by Christian Friedrich 
Bucholz and subsequently first synthesised in 1930 by Ernst Spath and Stephen Darling 
[22,23]. Capsaicin activates the transient receptor potential vanniloid 1 (TRPV1) ligand-gated 
channels of the peripheral Ad and C nociceptors. This causes depolarisation and the 
propagation of action potentials resulting in transmission of pain to the spinal cord with the 
resultant initial burning sensation experienced by patients [24]. After continued treatment, 
the TRPV1 containing nerves are “defunctionalised”, a term used to describe the epidermal 
nerve fibre degeneration that is seen on nerve biopsy in the area of application[25]. In clinical 
terms, this means that initiation of treatment is associated with a burning sensation for a 
number of days, followed by analgesia. It is available as 0.025% and 0.075% creams for 
application four times daily to the affected area, and as a one hour application of the 8% patch 
which, in the United Kingdom, is applied in the hospital setting so the patient can be 
supervised and monitored appropriately. Clinical trials involving 10% and 20% applications 
are currently in progress [26,27]. The 0.025-0.75% cream and 8% patch are approved for the 
treatment of peripheral neuropathic pain in the UK as 2nd line agents or in those who cannot 
tolerate systemic treatments, although the NICE guidelines comment that outside of post-
herpetic neuralgia and painful diabetic neuropathy the use is off-label and at the prescriber’s 
discretion [28,29]. 
A review of the recent literature by the authors did not yield a significant body of evidence 
for the use of capsaicin specifically in cancer-related pain, however there is a growing body 
of evidence in other localised neuropathic conditions suggesting a putative role.  
In the recent multi-centre randomised ‘ELEVATE’ trial involving 568 patients [30], the 
Capsaicin 8% patch was shown to be non-inferior to pregabalin in patients with painful non-
diabetic neuropathy. The withdrawal rate from the capsaicin group (6 of 282 patients) was 
low and attributed to patient choice (n=4) and perceived lack of effect (n=2). The systemic 
adverse event rate was 0-1% in the capsaicin group and 2.5-18.4% in the pregabalin group. 
Local adverse events were greater in the capsaicin group comprising pain on application (24% 
vs 0%), erytheyma (21% vs 0.4%, and a burning sensation (16% vs 0.4%). However, only 
patients in the pregabalin group (n=24, 8.5%) withdrew because of treatment- emergent 
adverse effects. The primary endpoint of 30% pain intensity reduction was reached by 55.7% 
in the capsaicin group and 54.5% in the pregabalin group. The time of onset to pain reduction 
was faster (7.5 days vs 36 days) and the treatment satisfaction was higher in the capsaicin 
group. The study was limited by its duration (8 weeks), the fact that a significant proportion 
of patients with LNP have already trialled gabapentinoids and the exclusion of patients with 
HIV neuropathy post radiotherapy neuropathy. That said, it was the first head to head study 
comparing these two readily available treatments and provided novel and clinically relevant 
information. The cost over a two year period for the two treatments has been considered 
relatively similar at £1,197 and £1,207 for capsaicin and pregabalin respectively[31]. 
The interval between 8% patch applications is determined by the individual patient’s response 
to treatment. Interim results from an ongoing phase IV, prospective, multicentre, non-
interventional ‘ASCEND’ study of routine practice using capsaicin patch in 296 patients 
demonstrated a median time to re-treatment of 5.5 months [32]. The capsaicin 8% patch can 
be considered a safe, relatively effective treatment in localised neuropathic pain. Despite the 
common local effects of erythema and burning discomfort on application, the rate of  
treatment discontinuation is low. 
OPIOIDS 
There are many transdermal opioid preparations available. Considering in isolation ‘topical’ 
opioid treatments as defined above, the evidence is conflicting. In a case series examining the 
use of topical morphine for arthritic pain, it was found to be an effective treatment. However, 
systemic absorption was evident from urinary analysis, thus negating both the advantages 
and claim of being a true topical treatment[33]. The concerns of systemic absorption and the 
resultant long-term side effects such as immunosuppression and impaired endocrine function 
are perhaps less significant in the palliative setting where a role for topical opioids may exist. 
It has been used in this context for painful mucositis but there is no substantial evidence for 
topical opioids in LNP[34]. 
MENTHOL 
A recent proof of concept study looked at the potential of menthol as a clinically useful 
analgesic in patients with chemotherapy induced peripheral neuropathy(CIPN) and scar 
related pain[35]. This was on the basis of basic science findings that activation of the TRPM8 
ion channel by topical agents produced significant analgesia[36]. The small numbered study 
found that 82% of subjects had an improvement in brief pain inventory (BPI) scores [35]. 
Improvements in mood (P = 0.0004), catastrophising (P = 0.001), walking ability (P = 0.008) 
and sensation (P < 0.01) were also observed. These results require to be validated on a larger 
scale but these limitations notwithstanding, menthol can be considered a safe inexpensive 
readily available treatment with potential efficacy in this patient group. 
OTHER TOPICAL ADJUNCTS 
A number of other drugs and drug combinations have been trialled for localised neuropathic 
pain. Clonidine has been used for sympathetically mediated peripheral neuropathy[37]. A 
small trial of topical amitriptyline 1%, an amitriptyline 1%/ketamine 0.5% combination, and 
placebo did not demonstrate a significant difference at 48hrs during the blinded phase of the 
study [38]. Interestingly no systemic absorption, as judged by serum sampling, was observed. 
In the subsequent open-label phase, combination therapy was significantly effective at 7 days. 
In a small number of patients with refractory radiation associated LNP, an amitriptyline-
ketamine-lidocaine combination cream was found to be safe and effective [39]. Ketamine has 
been used in topical preparations with concentrations of 2% with systemic absorption in less 
than 10% of subjects [40]. Beyond case reports involving mucositis, it has not been used 
extensively in the cancer setting [41]. Topical gabapentin has been used in a study of 51 
patients with vulvodynia to good effect but has not been extensively investigated in large 
number trials for LNP [42].  
Other treatments that have been trialled in small number studies include; dimethyl 
sulphoxide (DMSO), palmitoylethanolamide (PEA), and essential oxygen oil [43-45]. Although 
arguably not a topical treatment per se, intradermal botox has been recently shown in a 
randomised double-blinded controlled trial to have a sustained effect over 24 weeks when 
used in peripheral neuropathic pain[46]. In the palliative setting, radioactive strontium paste 
has been used to control pain from bony metastases[47]. 
CONCLUSION 
The treatment of neuropathic pain remains a difficult entity despite advances in our 
understanding of the pathophysiology and the increasing availability of novel treatments. The 
best systemic treatments are still only effective for 1 in 3 patients[10] and associated with 
intolerable side effects that limit their use in many. The use of topiceuticals in localised 
neuropathic pain associated with malignancy remain a valuable option with many advantages 
over systemic treatments as outlined above. In addition to anecdotal reports of efficacy, there 
is a growing body of evidence to consider the early use of topical lidocaine and capsaicin in 
this context. The authors’ have proposed a guideline including the use of topiceuticals to aid 
in the management of neuropathic pain (figure 1). The potential of other topical treatments 
such as opioids, ketamine, amitriptyline and gabapentinoids has yet to be established but 
small numbered trials have shown promising results.  
KEY POINTS 
 Simple scoring systems are available to aid in the diagnosis of localised neuropathic 
pain 
 Topiceuticals should be considered in a diagnosis of LNP, particularly in the frail and 
elderly population 
 Capsaicin and lidocaine patches are relatively safe and effective treatments for 
neuropathic pain 
 The role of other topiceuticals has yet to be fully evaluated but small numbered trials 
have shown promise 
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Table 1: A simple scoring tool for localised neuropathic pain (reproduced from [11]) 
Does the patient’s history suggest a relevant nerve lesion or disease? YES/NO 
Is the pain distribution neuroanatomically plausible? YES/NO 
Does the neurological examination reveal any negative or positive 
sensory sign in the area of the presumably lesioned nerve? 
YES/NO 
Is the most painful area circumscribed and smaller than an A4 paper? YES/NO 
3 Yes = probable neuropathic pain; 4 Yes = at least probable localised neuropathic pain 
 
 
 
 
 
 
 
 
Figure 1 
 
 
 
 
 
 
Legend. SMC = Scottish Medicines Consortium PDPN = Painful Diabetic Peripheral 
Neuropathy 
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